Education

Ph.D. National University of Singapore, Biochemistry, 2010
B.Sc. (Honors) National University of Singapore, Biochemistry, 2004

Work experience

Institutes of Biomedical Sciences and Children’s Hospital of Fudan University (2014-Present)
Cancer Center and Department of Pharmacology, University of California San Diego (2010-2014)
Institute of Molecular and Cell Biology, Singapore (2004-1010)

Contact

Address: 131 Dong’an Rd, Shanghai 200032

Email: fxyu@fudan.edu.cn

Lab homepage: http://yu-lab.fudan.edu.cn

Research Areas

Yu lab is interested to explore molecular mechanisms responsible for tissue development, regeneration, and cancer. Specific research topics include: 1) regulatory mechanisms and biological/pathological functions of the Hippo signaling pathway; 2) modeling and molecular targeting of cancers, such as gastrointestinal (GI) cancer and solid tumors in childhood; 3) cell migration/invasion. Methods frequently used in the lab include mouse genetics, organoid, imaging, sequencing (single cell), and computational biology. Currently, research associate, post-doc, research assistant, and graduate student positions are available, and we welcome self-motivated researchers or students to apply.

Selected Publications

1． Wang Y, Wang Y, Zhu Y, Yu P, Zhou F, Zhang A, Gu Y, Jin R, Li J, Zheng F, Yu A, Ye D, Xu Y, Liu YJ, Saw TB, Hu G, Lin CT, Yu FX*. Angiomotin cleavage promotes leader formation and collective cell migration. Developmental Cell. 2024 In press.

2． Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R, Gu Y, Wang Y, Ling C, Chen K, Ye D, Yu FX*. Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo. Cell Reports Medicine. 2024 In press.

3． Zhong Z, Jiao Z, Yu FX*. The Hippo signaling pathway in development and regeneration. Cell Reports. 2024 Mar 26;43(3):113926.

4． Wang Y, Zhu Y, Wang Y, Chang Y, Geng F, Ma M, Gu Y, Yu A, Zhu R, Yu P, Sha Z, Qi S, Li J, Zhao W, Pan W, Zhang R*, Yu FX*. Proteolytic activation of angiomotin by DDI2 promotes angiogenesis. TheEMBO Journal 2023 Jun 23:e112900.

5． Qi S, Zhong Z, Zhu Y, Wang Y, Ma M, Wang Y, Liu X, Jin R, Jiao Z, Zhu R, Sha Z, Dang K, Liu Y, Lim DS, Mao J, Zhang L, Yu FX*. Two Hippo signaling modules orchestrate liver size and tumorigenesis.TheEMBO Journal 2023 Jun 1;42(11):e112126.

6． Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, Tan L, Gan H, He C, Fang C, Lei Y, Li J, He C, Lan F, Shi X, Wei W, Wang Y, Ji Q, Yu FX*, Wang YL*.TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Science Advances 2023 Sep;9(35):eadg7125.

7． Yu A, Yu P, Zhu Y, Zhu R, Sun R, Ye D, Yu FX*.Glucose-induced and ChREBP: MLX-mediated lipogenic program promotes hepatocellular carcinoma development. Oncogene 2023 Sep 9;

8． Zhong Z, Meng Z, Yu FX*.Reconstructing the Hippo signaling network. Science Bulletin 2023 Aug 28; S2095-9273(23)00588-1 (Perspective).

9． Ma M, Zhong Z, Zhu Y, Gu Y, Jin R, Meng Z, Wang Y*, Yu FX*. Phosphorylation of NF2 at Serine-13 by MAP4K family kinases mediates pathological angiogenesis. Protein Cell 2023 Mar 16;14(2):137-142.

10．Gu Y, Wang Y, Sha Z, He C, Zhu Y, Li J, Yu A, Zhong Z, Wang X, Sun Y, Lan F, Yu FX*.Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers. Cell Reports 2022 Aug 30;40(9):111296.

11．Qi S, Zhu Y, Liu X, Li P, Wang Y, Zeng Y, Yu A, Wang Y, Sha Z, Zhong Z, Zhu R, Yuan H, Ye D, Huang S, Ling C, Xu Y, Zhou D, Zhang L, Yu, FX*. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Molecular Cell 2022 May 19;82(10):1850-1864.

12．Wang, Y., Zhu, Y., Gu, Y., Ma, M., Wang, Y., Qi, S., Zeng, Y., Zhu, R., Wang, X., Yu, P., Xu, J., Shu, Y., and Yu, FX*. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. Cell Reports Dec 7;14(712):eabj8393.

13．Li Y, Li J, Wang R, Zhang L, Fu G, Wang X, Wang Y, Fang C, Zhang D, Du D, Ma X, Pan M, Guo Q, Xu X, Hu X, Zhou Y, Mo S, Wang H, Gao J, Huang S, Liu Y, Cai S, Hua G*, Peng J*, Yu FX*. Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma. Protein & Cell 2020 Apr;11(4):292-298.

14．Pan, B., Yang, Y., Li, J., Wang, Y., Fang, C., Yu, FX.*, & Xu, Y. *(2020). USP47-mediated deubiquitination and stabilization of YAP contributes to the progression of colorectal cancer. Protein & Cell 11(2), 138-143.

15．Fang C, Li J, Qi S, Lei Y, Zeng Y, Yu P, Hu Z, Zhou Y, Wang Y, Dai R, Li J, Huang S, Xu P, Chen K, Ding C, Yu FX*. An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling. EMBO Reports 2019 Jun;20(6). pii: e47227.

16．Gong R, Hong AW, Plouffe SW, Zhao B, Liu G, Yu FX*,Xu Y*, Guan KL*. Opposing roles of conventional and nove PKC in the Hippo-YAP pathway regulation. Cell Research 2015 Aug;25(8):985-8.

17．Yu FX*, Zhao B, Guan KL*. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 2015 Nov 5;163(4):811-28 (Leading Edge Review).

18．Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, Guan KL. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014 Jun 16;25(6):822-30.

19．Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC, Guan KL. Protein Kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes & Development 2013 Jun 1;27(11):1223-32.

20．Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mill GB, Guan KL. Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling. Cell 2012 Aug 17;150(4):780-91.